Noradrenaline Kalceks (Norepinephrine)

Norepinephrine binds directly to alpha‑1 receptors on blood vessels, causing them to constrict, which elevates systemic vascular resistance. It also stimulates beta‑1 receptors in the heart, increasing contractility and heart rate, together improving cardiac output and arterial pressure.

The dosage of Noradrenaline Kalceks is individualized. A qualified prescriber determines the infusion rate based on the patient’s hemodynamic status, target blood pressure, and response to therapy. No fixed regimen is provided in public information.

The safety of norepinephrine in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and import documentation.

Norepinephrine is generally considered the first‑line vasopressor for most types of shock because of its balanced alpha‑1 and beta‑1 activity. Compared with agents such as phenylephrine (pure alpha) or dopamine (dose‑dependent), norepinephrine provides reliable blood‑pressure support with fewer tachyarrhythmic events.

The solution should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Maintaining the cold chain preserves potency and prevents degradation before use.

Noradrenaline Kalceks is supplied as a sterile solution for injection and is given intravenously, typically via a central venous catheter. The infusion is started at a low rate and titrated to achieve the desired blood‑pressure target under continuous monitoring.

Serious risks include severe hypertension, cardiac arrhythmias, myocardial ischemia, and tissue necrosis if the drug extravasates from the vein. Prompt recognition of these events and immediate medical intervention are essential to mitigate harm.

Patients with known hypersensitivity to norepinephrine or any component of the formulation should avoid its use. Caution is also advised in individuals with uncontrolled hypertension, severe peripheral vascular disease, or those receiving MAO inhibitors, unless the clinical situation mandates its use.